Compare Centrus Energy Corp (LEU) vs Novavax Inc (NVAX) Price & Performance

Centrus Energy (LEU) trades at $189.03, down 0.16% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 revenue of $176.1 million, beating expectations, but net income declined to $16.8 million from $28.9 million year-over-year due to higher costs. Recent developments include a $900 million DOE contract and a HALEU supply agreement with X-energy, positioning Centrus as a key player in the nuclear fuel supply chain with a $4.5 billion backlog.

The outlook for LEU is positive given its strategic role in nuclear energy expansion and strong institutional support, but risks include margin compression and execution challenges. Analysts maintain a buy consensus with a $228.50 price target, representing 21% upside potential from current levels.

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.